EMEA-003528-PIP01-23 - paediatric investigation plan
empasiprubart
PIPHuman
Key facts
- Active Substance
- empasiprubart
- Therapeutic area
- Nervous system disorders
- Decision number
- P/0093/2024
- PIP number
- EMEA-003528-PIP01-23
- Pharmaceutical form(s)
- All pharmaceutical forms
- Condition(s) / indication(s)
- Treatment of multifocal motor neuropathy (MMN)
- Route(s) of administration
- All routes of administration
- Contact for public enquiries
argenx BV
E-mail: regulatory@argenx.com
Tel: +32 93103400- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date